Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2300360120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Kailu Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: HHMI, Stanford University, Stanford, CA 94305. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, Howard Hughes Medical Institute.
Abstract (Originalsprache)
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) introduced a relatively large number of mutations, including three mutations in the highly conserved heptad repeat 1 (HR1) region of the spike glycoprotein (S) critical for its membrane fusion activity. We show that one of these mutations, N969K induces a substantial displacement in the structure of the heptad repeat 2 (HR2) backbone in the HR1HR2 postfusion bundle. Due to this mutation, fusion-entry peptide inhibitors based on the Wuhan strain sequence are less efficacious. Here, we report an Omicron-specific peptide inhibitor designed based on the structure of the Omicron HR1HR2 postfusion bundle. Specifically, we inserted an additional residue in HR2 near the Omicron HR1 K969 residue to better accommodate the N969K mutation and relieve the distortion in the structure of the HR1HR2 postfusion bundle it introduced. The designed inhibitor recovers the loss of inhibition activity of the original longHR2_42 peptide with the Wuhan strain sequence against the Omicron variant in both a cell–cell fusion assay and a vesicular stomatitis virus (VSV)-SARS-CoV-2 chimera infection assay, suggesting that a similar approach could be used to combat future variants. From a mechanistic perspective, our work suggests the interactions in the extended region of HR2 may mediate the initial landing of HR2 onto HR1 during the transition of the S protein from the prehairpin intermediate to the postfusion state.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HHMI, Stanford University, Stanford, CA 94305.
- Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305.
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.
- Department of Structural Biology, Stanford University, Stanford, CA 94305.
- Department of Photon Science, Stanford University, Stanford, CA 94305.
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115.
ORCID-Profile: Kailu Yang, Alex J B Kreutzberger, K Ian White, Axel T Brunger
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- Howard Hughes Medical Institute
- HHS | National Institutes of Health
Zitieren
APA
Yang, K., Wang, C., Kreutzberger, A. J. B., White, K. I., Pfuetzner, R. A., Esquivies, L., Kirchhausen, T., & Brunger, A. T. (2023). Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2300360120
Vancouver
Yang K, Wang C, Kreutzberger AJB, White KI, Pfuetzner RA, Esquivies L, et al. Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2300360120
BibTeX
@article{Yang2023,
author = {Yang, Kailu and Wang, Chuchu and Kreutzberger, Alex J B and White, K Ian and Pfuetzner, Richard A and Esquivies, Luis and Kirchhausen, Tomas and Brunger, Axel T},
title = {Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2300360120}
}
EUVIMED